User login
In the August podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses recent approvals by the Food and Drug Administration – for uridine triacetate as an antidote for 5-fluorouracil overdose and toxicity, and for two therapies for multiple myeloma, the monoclonal antibody elotuzumab and the proteasome inhibitor ixazomib. Also in this month’s line-up are study findings on abnormal vaginal bleeding and contraception counseling in women who are undergoing chemotherapy; the effects of IV iron treatment with ferumoxytol on health-related quality of life of patients with iron deficiency anemia; and on mindfulness-based cancer recovery in survivors recovering from chemotherapy and radiation. Two Case Reports focus on gastrointestinal cancers, one in a patients with high-grade leiomyosarcoma of the transverse colon and who presented with bowel perforation, and another on 1,25-dihydroxyvitamin D hypercalcemia and imatinib hepatotoxicity in a patient with GIST, and the New Therapies feature provides a detailed examination of recent advances in managing gynecologic cancers.
Listen to the podcast below.
In the August podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses recent approvals by the Food and Drug Administration – for uridine triacetate as an antidote for 5-fluorouracil overdose and toxicity, and for two therapies for multiple myeloma, the monoclonal antibody elotuzumab and the proteasome inhibitor ixazomib. Also in this month’s line-up are study findings on abnormal vaginal bleeding and contraception counseling in women who are undergoing chemotherapy; the effects of IV iron treatment with ferumoxytol on health-related quality of life of patients with iron deficiency anemia; and on mindfulness-based cancer recovery in survivors recovering from chemotherapy and radiation. Two Case Reports focus on gastrointestinal cancers, one in a patients with high-grade leiomyosarcoma of the transverse colon and who presented with bowel perforation, and another on 1,25-dihydroxyvitamin D hypercalcemia and imatinib hepatotoxicity in a patient with GIST, and the New Therapies feature provides a detailed examination of recent advances in managing gynecologic cancers.
Listen to the podcast below.
In the August podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses recent approvals by the Food and Drug Administration – for uridine triacetate as an antidote for 5-fluorouracil overdose and toxicity, and for two therapies for multiple myeloma, the monoclonal antibody elotuzumab and the proteasome inhibitor ixazomib. Also in this month’s line-up are study findings on abnormal vaginal bleeding and contraception counseling in women who are undergoing chemotherapy; the effects of IV iron treatment with ferumoxytol on health-related quality of life of patients with iron deficiency anemia; and on mindfulness-based cancer recovery in survivors recovering from chemotherapy and radiation. Two Case Reports focus on gastrointestinal cancers, one in a patients with high-grade leiomyosarcoma of the transverse colon and who presented with bowel perforation, and another on 1,25-dihydroxyvitamin D hypercalcemia and imatinib hepatotoxicity in a patient with GIST, and the New Therapies feature provides a detailed examination of recent advances in managing gynecologic cancers.
Listen to the podcast below.